CervoMed Data Suggests Neflamapimod's Potential in Pure DLB
Event summary
- CervoMed presented new clinical, biomarker, and imaging data for neflamapimod at AAIC 2026.
- Phase 2b trial results indicate neflamapimod slowed DLB progression in patients with low plasma pTau181 levels.
- New PK-PD analysis supports a 50 mg TID dose for planned Phase 3 trial, expected to achieve target plasma concentrations in ~90% of patients.
- An 80 mg BID dose met safety and tolerability objectives in a separate Phase 2 study.
The big picture
CervoMed's data suggests neflamapimod could address the underlying cause of DLB, reinforcing the basal forebrain as a key therapeutic target. The findings come amid growing interest in targeted treatments for neurodegenerative diseases, particularly those with no approved therapies. CervoMed's ability to secure partnerships and navigate regulatory pathways will be critical in advancing this candidate.
What we're watching
- Regulatory Alignment
- Whether CervoMed can sustain alignment with global regulators for the Phase 3 trial design.
- Dosing Optimization
- The pace at which CervoMed can finalize and implement the optimal dosing strategy for neflamapimod.
- Strategic Partnerships
- How quickly CervoMed secures a strategic partner to fund and advance the Phase 3 trial.